Nasdaq suspends Windtree (WINT): -80% in 24 hours, moving to OTC and BNB strategy in jeopardy

Related

American Bitcoin Q3 results show $126M profit despite margin pressure

American Bitcoin’s Q3 results showed a return to profit...

Stem stock jumps 21.94%, but stays below all three daily EMAs

Stem stock retains a bearish daily bias despite a...

Curis stock jumps 59.15% to $1.13, but daily trend stays unresolved

Curis stock retains a neutral daily outlook despite a...

Cricut stock jumps 49.08% to $8.90, but daily RSI hits overbought territory

Cricut stock has a bullish daily setup, but overbought...

Share

The suspension from Nasdaq for Windtree Therapeutics (ticker WINT), due to non-compliance with listing requirements and accompanied by an intraday collapse of –80%, has sparked strong fears among investors and raised questions about the recent initiative of treasury in BNB (initial commitment of $60 million with potential up to $200 million), indicating an already fragile financial balance.

According to the collected data, the stock went from about $0.48 before the notice to $0.11 at the close on August 21, 2025, confirming the very substantial intraday loss. Industry analysts monitoring small-cap biotech companies note that similar situations typically lead to a compression of capitalization and a significant reduction in liquidity in the first weeks following the delisting.